Invention Grant
- Patent Title: Compounds inhibiting leucine-rich repeat kinase enzyme activity
-
Application No.: US15507577Application Date: 2015-08-28
-
Publication No.: US10954240B2Publication Date: 2021-03-23
- Inventor: Xing Dai , Kallol Basu , Duane DeMong , Sarah W. Li , Michael Miller , Jack D. Scott , Andrew W. Stamford
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Sylvia A. Ayler; Catherine D. Fitch
- International Application: PCT/US2015/047318 WO 20150828
- International Announcement: WO2016/036586 WO 20160310
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D413/14 ; C07D487/04 ; C07D403/14 ; C07D401/04 ; C07D403/04 ; A61P25/16
Abstract:
The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R9, and A are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Public/Granted literature
- US20180230152A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY Public/Granted day:2018-08-16
Information query
